Association between STAT3 gene Polymorphisms and Crohn’s disease susceptibility: a case–control study in a Chinese Han population

Zhengting Wang1†, Bin Xu1†, Hongxin Zhang2, Rong Fan1, Jie Zhou1 and Jie Zhong1*

Abstract

Background: Crohn’s disease (CD) is an immune-related disease with genetic predisposition. This study aimed to investigate the association of three polymorphisms in the signal transducer and activator of transcription 3 (STAT3) gene with CD risk in a Chinese population.

Methods: We conducted a hospital-based case–control study involving 232 CD patients and 272 controls. Genotyping was performed using polymerase chain reaction with sequence-specific primer method. Statistical analyses were conducted using logistic regression and genotype risk scoring.

Results: Significant differences were found between patients and controls in allele/genotype distributions of rs744166 (Pallele = 0.0008; Pgenotype = 0.003) and allele distributions of rs4796793 (P = 0.03). The risk for CD associated with the rs744166-A mutant allele decreased by 37% [95% confidence interval (CI): 0.48–0.83] under the additive model, 39% (95% CI: 0.43–0.81) under the dominant model and 57% (95% CI: 0.24–0.77) under the recessive model. Carriers of the rs4796793-G mutant allele exhibited 25% (95% CI: 0.58–0.98; P = 0.03) and 47% (95% CI: 0.30–0.95) decreased risks of developing CD under the additive and recessive models, respectively.

Conclusions: STAT3 rs744166 and rs4796793 polymorphisms may be associated with CD occurrence and used as a predictive factor of CD in Chinese Han populations.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2169674321122294

Keywords: STAT3, Polymorphism, Crohn’s diseases, Susceptibility, Association study

Background

Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBDs). The etiology and pathogenesis of CD are not completely understood. However, familial aggregation and twin studies report that patients with CD carry strong genetic predisposition [1]. Several studies also strongly suggest that CD results from a combination of factors, such as commensal bacteria, food antigens, immunologic factors and multiple genetic factors [2,3]. The signal transducer and activator of transcription 3 (STAT3) gene is a potential candidate gene for CD for several reasons. STAT3 is a member of STAT family, which possesses an important function in the development of human immune system and haematopoiesis. This gene has been associated with the signal transduction pathway of multiple cytokines, including IL-2/γc, IL-6/gp130, IFN and IL-10 families, as well as IL-12, IL-23, Flt3 ligand, M-CSF, G-CSF, leptin and growth hormone [4-9]. Several studies have highlighted that the STAT3 signaling pathway is important in the occurrence and development of IBD both in patients and animal models [10-13].

In 2008, Barrett et al. [14] reported that the STAT3 locus is significantly associated with CD susceptibility in a genome-wide association study (GWAS). Since then, a number of studies have demonstrated that the polymorphisms of STAT3 are associated with CD as well as UC,
but their results are not consistent in different population cohorts [15-20]. Therefore, we performed an analysis on three polymorphisms (rs2293152, rs4796793 and rs744166) of STAT3 and CD in Chinese Han population.

**Methods**

**Patient and control subjects**

This hospital-based case–control study involved 232 CD patients and 272 healthy controls of Chinese Han population recruited from the Department of Gastroenterology of Ruijin Hospital, which is connected with the Shanghai Jiaotong University School of Medicine between January 2009 and December 2010. Senior physicians diagnosed all patients based on clinical, endoscopic, radiological and histopathological findings in accordance with previously established international criteria [21]. All patients were followed up at least for 1 year and registered with an integrated clinical and epidemiological registry. Controls were randomly selected from healthy persons under routine health screening. The present study was performed in accordance with the principles of Declaration of Helsinki and approved by the Research Ethics Committee of Ruijin Hospital, Shanghai, China. Informed consent was obtained from all subjects before blood sampling was carried out.

**Genotyping**

Genomic DNA was isolated from Ethylene Diamine Tetraacetic Acid (EDTA) peripheral blood using the QIAamp blood extraction kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. All DNA samples were genotyped for single nucleotide polymorphisms by polymerase chain reaction with sequence-specific primers (PCR-SSPs). All primers for the PCR-SSPs were designed using the genomic sequences in GenBank (http://www.ncbi.nlm.nih.gov). The primer sequences are listed in Table 1. The amplified products were assessed for the presence/absence of PCR amplicons specific to particular alleles using a standard 2% agarose gel electrophoresis, followed by ethidium-bromide staining. About 10% of the samples were then confirmed by sequencing.

**Statistical analysis**

For continuous and categorical variables, unpaired $t$-test and $\chi^2$ were conducted to compare CD patients and controls, respectively. To avoid gross genotyping error, all polymorphisms were evaluated for consistency with Hardy–Weinberg equilibrium on a contingency table of observed-versus-predicted genotype frequencies by using Pearson $\chi^2$ test or Fisher’s exact test. Genotypes were compared by logistic regression analysis under assumptions of additive, dominant and recessive models of inheritance. A $P < 0.05$ was considered statistically significant.

**Results**

Table 2 shows detailed information of patients and controls. Cases and controls were well matched by age and gender distribution.

The frequencies and distributions of alleles and genotypes at rs2293152, rs4796793 and rs744166 STAT3 were identified and compared between CD patients and controls. The genotype distributions of the three polymorphisms of STAT3 were in Hardy–Weinberg equilibrium in control groups ($P > 0.05$).

Table 3 shows that a significant difference was observed for rs744166 between CD patients and controls both in allele and genotype distributions ($P_{\text{allele}} = 0.0008$, and $P_{\text{genotype}} = 0.003$). A significant decreased risk was identified for rs744166 in association with CD under the additive (odds ratio (OR) = 0.63; 95% confidence interval (CI): 0.48–0.83), dominant (OR = 0.61; 95% CI: 0.43–0.81) and recessive (OR = 0.43; 95% CI: 0.24–0.77) models.

As for rs4796793, a significant difference was observed between the two groups in allele but not in genotype distribution ($P_{\text{allele}} = 0.03$ and $P_{\text{genotype}} = 0.07$). Meanwhile,

| rs2293152 | Internal control forward primer | CCCTTTAACCTAAACTTCAT |
|-----------|---------------------------------|-----------------------|
|           | Common reverse primer            | CCAGTGTCTTTATCCATCCC |
|           | Specific primer C                | ACAAAGGGCTCTGCTGGTCC |
|           | Specific primer G                | AAAGGCGCTCTGCTGGCC   |
| rs4796793 | Internal control forward primer  | TCTGGTAGACACGCTCACTAC |
|           | Common reverse primer            | CCATAGTCGCCAGAGTATTAT |
|           | Specific primer C                | TGTGTTGAGTTTACCTGTAC |
|           | Specific primer G                | GTGTGTGAGTTTACCTGTAC |
|           | Internal control forward primer  | TGCCCTGCTGCTTTTCTTG |
|           | Common reverse primer            | GATGGGACTTGCTGACTTG  |
|           | Specific primer C                | TGCTTGAGGCAATCGAGCC  |
|           | Specific primer G                | ATGCTTGAAGGAAATCGACT |
We examined three polymorphisms of STAT3 in 232 CD patients and 272 normal controls of Chinese Han population. Results revealed that both the STAT3 gene alleles of rs4796793G and rs744166C reduced the risk of CD occurrence and may have a protective function in CD. To the authors’ knowledge, this is the pilot study that explored the genetic susceptibility of STAT3 gene to CD in a Chinese population.

The rs744166, which was first identified as an important candidate susceptibility locus for CD in a GWAS research [14], was confirmed in a Chinese population in this study. Our results are in agreement with those previously published data in a New Zealand population [17]. They found a significant decrease in the frequency of the G allele of rs744166 in CD patients compared with controls (OR = 0.76, 95% CI = 0.61–0.95, P = 0.013), and G allele may be protective against CD. However, Franke et al. [15] failed to replicate the association between rs744166 and CD risk in a German population. This discrepancy may be mostly due to the heterogeneous genetic predispositions in people of different ethnicities. The genetic markers in predisposition to IBD vary across geographical and racial groups. In our previous meta-analyses, the CD14 gene C-260 T polymorphism exhibits remarkable heterogeneity with UC across ethnic groups, which is significant in Asians but not in Caucasians [27]. However, given the relatively small samples in this study, more studies are required to reliably quantify the effect of rs744166.

rs2293152, a STAT3 variant, has been reported to be significantly associated with CD in Japanese population [16]. This variant did not show significant association between CD patient and normal control groups in this study. Sample size may be one of the major determinants because both studies (Sato’s research and our study) selected East Asia population. Sato’s study only enrolled 83 CD cases and 200 healthy controls, whereas our study included 232 CD cases and 272 normal controls. Given the larger sample size, our result seems more reliable. We could not exclude the different population results in different genetic backgrounds.

In the present study, a new candidate locus, rs4796793, was found, which was associated with CD in Chinese population. This association is not reported in other studies. Therefore, further studies should be carried out to verify this association using a large sample size from different ethnic origins and biological research.

This study has some drawbacks. First, the sample size was not very large; thus, more SNP sites for pair-loci D'/r2 value analysis and haplotype analysis on a larger number of Chinese subjects and on other ethnicities are necessary to confirm the association more clearly. Second, we only revealed limited polymorphisms of STAT3 gene associated with susceptibility to CD, and other unidentified

### Table 2 Characteristics of CD patients and healthy controls in the Chinese Han population

| Characteristics | CD patients | Control subjects |
|-----------------|-------------|------------------|
| Number          | 232         | 272              |
| Age, mean ± SD (years) | 33.6 ± 13.5 | 46.4 ± 9.8       |
| Age range (years) | 20-70       | 18-70            |
| Male /female    | 149/83      | 172/100          |
| Smoking (%)     | 53 (22.84)  | 67 (24.63)       |
| Drinking (%)    | 32 (13.79)  | 39 (14.34)       |
| Appendectomy (%)| 15 (6.47)   | 18 (6.62)        |
| Family history of CD | 0           | 0                |

a significant decreased risk was found in association with CD under the additive (OR = 0.75; 95% CI: 0.58–0.98) and recessive (OR = 0.53; 95% CI: 0.30–0.95) models, whereas no significant association was detected under the dominant model (OR = 0.76; 95% CI: 0.57–1.09).

No significant difference was observed in the genotype and allele distributions of rs2293152 between CD patients and controls. This result also agrees under the assumptions of the additive (OR = 0.94; 95% CI: 0.73–1.23), dominant (OR = 1.19; 95% CI: 0.80–1.77) and recessive (OR = 0.66; 95% CI: 0.42–1.05) models.

### Discussion

CD is a relapsing inflammatory condition of gastrointestinal mucosal damage with characteristic extra-intestinal manifestations [22,23]. CD is widely known as an immune-related disease with genetic predisposition. Given the importance of immunity in CD, investigations on CD-susceptibility genes that involve immunity have attracted considerable attention [24,25].

The STAT3 gene is located on chromosome 17q21. Its protein product is a member of the STAT protein family that performs a dual function: signal transduction and transcription activation. STAT3 is widely expressed and a latent cytoplasmic transcription factor that relays signals from the cell membrane directly to the nucleus. STAT3 becomes activated through phosphorylation on tyrosine as a DNA-binding protein in response to a variety of stimuli and mediates the expression of a variety of genes. Thus, STAT3 possesses a key function in many biological pathways crucial to cell function, including proliferation, migration, survival and differentiation [26]. Several studies indicated that STAT3 activation plays distinctly different roles between innate and acquired immune responses in colitis, that is, activation of STAT3 in innate immune cells enhances mucosal barrier function and STAT3 activation in T-cells exacerbates colitis [11,12]. A number of studies also suggest that polymorphisms of STAT3 are associated with the susceptibility of CD or UC in some population cohorts [15-20].
Table 3: The genotype distributions and allele frequencies of the studied polymorphisms between patients and controls, and their risk prediction for CD under three genetic models of inheritance

| Polymorphism | CD group (%) | Healthy control (%) | $\chi^2$ | $P^\dagger$ | allele | CD group (%) | Healthy control (%) | $\chi^2$ | $P^\ddagger$ | CD group HWe | P | Healthy control HWe | P |
|--------------|--------------|---------------------|---------|-----------|--------|--------------|---------------------|---------|-----------|----------------|---|-------------------|---|
| rs2293152    | GG 58 (25.2) | 78 (28.7)           |         |           | G 253 (55.0) | 292 (53.7) |         |           | 5.16 | 0.08 | 0.18 | 0.67 | 0.21 | 0.93 |
|              | CG 137 (59.6)| 136 (50)            |         |           | C 207 (45.0) | 252 (46.3) |         |           | 0.18 | 0.67 | 0.21 | 0.93 |
|              | CC 35 (15.2) | 58 (21.3)           |         |           | 0.18 | 0.67 | 0.21 | 0.93 |
|              | OR; 95% CI; P| Additive model: 0.94 (0.73, 1.23); 0.66 |       | Dominant model: 1.19; (0.8, 1.77); 0.39 |   | Recessive model: 0.66; (0.42, 1.05); 0.08 | |
| rs4796793    | CC 111 (47.8)| 112 (41.2)          |         |           | C 324 (69.8) | 345 (63.4) |         |           | 5.38 | 0.07 | 4.61 | 0.03 | 0.51 | 0.50 |
|              | CG 102 (44.0)| 121 (44.5)          |         |           | G 140 (30.2) | 199 (36.6) |         |           | 0.18 | 0.67 | 0.21 | 0.93 |
|              | GG 19 (8.2)  | 39 (14.3)           |         |           | 0.18 | 0.67 | 0.21 | 0.93 |
|              | OR; 95% CI; P| Additive model: 0.75 (0.58, 0.98); 0.03 |       | Dominant model: 0.76; (0.57, 1.09); 0.13 |   | Recessive model: 0.53; (0.30, 0.95); 0.03 | |
| rs744166     | TT 106 (48)  | 98 (36.2)           |         |           | T 309 (69.9) | 323 (59.6) |         |           | 11.62 | 0.003 | 11.28 | 0.0008 | 0.52 | 0.66 |
|              | CT 97 (43.9) | 127 (46.9)          |         |           | C 133 (30.1) | 219 (40.4) |         |           | 11.62 | 0.003 | 11.28 | 0.0008 | 0.52 | 0.66 |
|              | CC 18 (8.1)  | 46 (16.9)           |         |           | 0.18 | 0.67 | 0.21 | 0.93 |
|              | OR; 95% CI; P| Additive model: 0.63 (0.48, 0.83); <0.001 |       | Dominant model: 0.61; (0.43, 0.81); 0.008 |   | Recessive model: 0.43; (0.24, 0.77); 0.005 | |

Abbreviations: HWe Hardy-Weinberg equilibrium. $P$ values were calculated using $\chi^2$ test for genotype distributions and 2 × 2 contingency table for allele distributions. OR, 95% CI and $P$ values were calculated by logistic regression analysis.
polymorphisms, which influenced the development of CD, may still exist. Third, our results were based on unadjusted estimates. STAT3 gene polymorphisms of rs4796793 and rs744166 individually make a protective contribution against CD, but whether the polymorphisms integrated with other risk factors will change the prediction requires additional research. Thus, a more precise analysis should be conducted with individual data, which would allow for the adjustment by other co-variables, such as age, gender, lifestyle and other genetic factors.

Conclusion
In conclusion, this study is the first to demonstrate the single-marker association of STAT3 with CD susceptibility in the Chinese Han population. We confirmed that STAT3 rs744166 and rs4796793 polymorphisms were associated with CD occurrence and used as a predictive factor of CD in Chinese Han populations. However, the diverse genetic profiles across different ethnic groups remain unclear.

Abbreviations
CD: Crohn’s disease; STAT3: Signal transducer and activator of transcription 3; CI: Confidence interval; UC: Ulcerative colitis; IBD: Inflammatory bowel disease; GWAS: Genome-wide association study; EDTA: Ethylene Diamine Tetraacetic Acid; PCR-SSPS: Polymerase chain reaction with sequence-specific primers; OR: Odds ratio.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
ZTW, BX, HXZ and J. Zhong conceived and designed the study. ZTW, HXZ, carried out the experiments and drafted the manuscript. RF, J. Zhou participated in the statistical analysis. All authors read and approved the final manuscript.

Author details
1Department of Gastroenterology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China. 2State Key Laboratory of Medical Genomics, Research Center for Experimental Medicine, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

Received: 4 November 2013 Accepted: 11 May 2014

References
1. Zheng CQ, Hu GZ, Zeng ZS, Lin LJ, Gu GQ. Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning. World J Gastroenterol 2003, 9(8):1646–1656.
2. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterology hepatology(NY) 2010, 6(5):339–346.
3. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008, 8(6):458–466.
4. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178(5):2623–2629.
5. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008, 28(4):477–487.
6. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000, 19(21):2607–2611.
7. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Förster I, Akira S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999, 10(1):39–49.
8. Stumhofer JS, Silver JS, Laurence A, Poretz PM, Harris TH, Turka LA, Ernst M, Saris CJ, O’Shea JJ. Hunter CA: Interleukins 27 and 6 induce STAT3-mediated p3 cell production of interleukin 10. Nat Immunol 2007, 8(12):1363–1371.
9. Losau Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Fasl-dependent dendritic cell differentiation. Immunity 2003, 19(6):903–912.
10. Suzuki A, Hanada T, Mitsuhashi K, Yoshida T, Tsuchiya K, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A. C15S/SC53/S153 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001, 193(4):471–481.
11. Musso A, Dentiell P, Cattino A, Chiusa L, Repici A, Stum A, Fizzaro C, Rizzetto M, Pegoraro L, Sategna Guidetti C, Brici MF. Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis 2005, 11(2):91–98.
12. Lovato P, Brendler C, Aghsolt J, Kelsen J, Kalfkoff T, Svejgaard A, Eriksen RN, Woetmann M, Oeum N. Constitutive STAT3 activation in intestinal T cells from patients with Crohn’s disease. J Biol Chem 2003, 278(19):16777–16781.
13. Li Y, de Haar C, Peppelenbosch MP, van der Woude CJ. New insights into the role of STAT3 in IBD. Inflamm Bowel Dis 2012, 18(6):1177–1183.
14. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Bamman MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Groop L, Kottke FE, Kuick R, Leppert M, Loh ML, Lu T, Schueler T, Schumm LP, Steinhardt AH, Targan SR, Xavier RJ. Genetics Consortium. NIDDK IBD, Libioulle C, Sandor C, Lathrop M, Belache J, Dewt O, Gut I, et al: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 2008, 40(4):955–962.
15. Franke A, Balaschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldts D, Nikolaus S, Rosenstiel P, Krawczak M, Schreiber S. Replication of signals from recent studies of Crohn’s disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008, 40(6):713–715.
16. Sato K, Shiota M, Fukuda S, Iwamoto E, Machida H, Inamine T, Kondo S, Yanagihara K, Isomoto H, Muta M, Kohno S, Tsukamoto K. Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn’s disease in the Japanese population. J Clin Immunol 2009, 29(6):815–825.
17. Fergusson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, Duan H, Karunasngee N: Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat Res 2010, 690(1–2):108–115.
18. Cénit MC, Alcina A, Márquez A, Mendoza JL, Díaz-Rubio M, de las Heras V, Izquierdo G, Arroyo R, Fernández O, de la Concha EG, Matesanz F, Urcelay E. STAT3 locus in inflammatory bowel disease and multiple sclerosis susceptibility. Genes Immun 2010, 11(3):264–268.
19. Peter I, Mitchell AA, Ozellus L, Erazo M, Hu L, Dohoney D, Abreu ML, Present DH, Ullman T, Benkov K, Korelitz B, Mayer L, Desnick RJ, New York Crohn’s Disease Working Group: Evaluation of 22 genetic variants with Crohn’s disease risk in the Ashkenazi Jewish population: a case–control study. BMC Med Genet 2011, 12:63.
20. Polgar N, Csongei V, Szabo M, Somogyi V, Nagy G, Eriksen KW, Woetmann A, Ødum N. STAT3-mediated T cell production of interleukin 10. Endocrinology 2007, 148(12):6295–6302.
21. Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, Lam SK, Xiao SD: STAT3 is required for Flt3L-dependent hematopoiesis. J Immunol 2008, 180(5):2623–2629.
22. Matalka II, Al-Omari FA, Salama RM, Mohtaseb AH: A novel approach for quantitative assessment of mucosal damage in inflammatory bowel disease. Diagnostic Pathology 2013, 8:156.
23. Larsen EP, Bayar A, Vyberg M: Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the literature. Diagnostic Pathology 2012, 7:1100.
24. Wang ZT, Hu JI, Fan R, Zhou J, Zhong J. RAGE gene three polymorphisms with Crohn’s disease susceptibility in Chinese Han population. World J Gastroenterol 2014, 20(8):2497–2502.
25. Wang L, Wang ZT, Hu JJ, Fan R, Zhou J, Zhong J. Polymorphisms of the vitamin D receptor gene and the risk of inflammatory bowel disease: a meta-analysis. Genet Mol Res 2014, 13(2):2598–2610.

26. Levy DE, Darnell JJ. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3(9):651–662.

27. Wang Z, Hu J, Fan R, Zhou J, Zhong J. Association between CD14 gene C-260 T polymorphism and inflammatory bowel disease: a meta-analysis. PLoS One 2012, 7:e45144.

doi:10.1186/1746-1596-9-104

Cite this article as: Wang et al.: Association between STAT3 gene Polymorphisms and Crohn’s disease susceptibility: a case–control study in a Chinese Han population. Diagnostic Pathology 2014 9:104.